Beta Bionics, Inc.
As of Oct 22, 2026, Beta Bionics is in Stage 2, the uptrend phase, now in week 8 (since Sep 1, 2026). It closed at $19.34, 39.5% below its 52-week high and above its 200-day average, which is falling.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care
Is BBNX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BBNX among Medical Devices55th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …55 | BBNX | Stage 2 · wk 8 | 48 | −12.8% |
Beta Bionics: quick answers
What stage is Beta Bionics in?
As of Oct 22, 2026, Beta Bionics (BBNX) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 1, 2026 and is in week 8. What the four stages mean
Is Beta Bionics in an uptrend?
Yes. Beta Bionics is in a Stage 2 uptrend. It trades 29.5% above its 200-day average, which is falling.
How far is Beta Bionics from its 52-week high?
Beta Bionics closed at $19.34 on Oct 22, 2026, 39.5% below its 52-week high of $31.99. Its 52-week low is $8.86.
How has Beta Bionics performed over the past year?
As of Oct 22, 2026, Beta Bionics is down 7.8% over the past year and down 33.9% so far in 2026.
Which sector and industry is Beta Bionics in?
Beta Bionics is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.